Summit Therapeutics PLC | |
Stock Exchange | London Stock Exchange |
EPS |
GBP0.15 |
Market Cap |
GBP38.12 M |
Shares Outstanding |
82.13 M |
Public Float |
76.37 M |
Summit Therapeutics PLC ADR | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1 |
Market Cap |
$41.41 M |
Shares Outstanding |
32.1 M |
Public Float |
- |
Address |
136a Eastern Avenue Abingdon Oxfordshire OX14 4SB United Kingdom |
Employees | - |
Website | http://summitplc.com |
Updated | 07/08/2019 |
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom. |